Hospital Amaral Carvalho

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Acute myeloid leukaemia2 trials
• Lung cancer2 trials
• Multiple myeloma2 trials
• Bladder cancer1 trial
• Melanoma1 trial
• Metastatic breast cancer1 trial
• Myelodysplastic syndromes1 trial
• Myeloproliferative neoplasms1 trial

Phase

• Phase 39 trials
• Phase 21 trial

Status

• Active, not recruiting5 trials
• Recruiting3 trials
• Completed1 trial
• Not yet recruiting1 trial

Lead sponsor

• Hoffmann-La Roche2 trials
• Pfizer2 trials
• Taiho Oncology, Inc.2 trials
• Hospital Municipal São José1 trial
• Institut de Recherches Internationales Servier1 trial
• and 2 more

Running trials

• Recruiting

  A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

  NCT07128199· Phase 3· Taiho Oncology, Inc.· Source

  Contact: Taiho Oncology, Inc.

• Recruiting

  Photodynamic Therapy Associated With Sonodynamic Therapy for the Treatment of Nodular Basal Cell Carcinoma

  NCT07381972· Phase 3· University of Sao Paulo· Source

  Contact: Ana G Salvio, Doctor

• Recruiting

  MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  NCT06152575· Phase 3· Pfizer· Source

• Active, not recruiting

  REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

  NCT05973773· Phase 3· Taiho Oncology, Inc.· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

  NCT06065748· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia

  NCT06537843· Phase 2· Hospital Municipal São José· Source

  Contact: Ederson Mattos, MD

• Active, not recruiting

  Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

  NCT05317416· Phase 3· Pfizer· Source

• Active, not recruiting

  A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

  NCT03165734· Phase 3· Swedish Orphan Biovitrum· Source

• Active, not recruiting

  Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

  NCT03173248· Phase 3· Institut de Recherches Internationales Servier· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukaemia1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting
• Multiple myeloma1 recruiting

Closed trials

• Completed

  A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

  NCT04660344· Phase 3· Hoffmann-La Roche· Source